Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» October 2013
October 2013
Novo Nordisk recruiting 400 U.S. sales reps as growth decelerates
Novo Nordisk recruiting 400 U.S. sales reps as growth decelerates
Fierce Pharma
hirings
Novo Nordisk
Bayer Third-Quarter Earnings Rise on New Medicines
Bayer Third-Quarter Earnings Rise on New Medicines
Bloomberg
earnings
Bayer
Mazor Robotics prices $41M offering
Mazor Robotics prices $41M offering
Mass Device
Mazor Robotics
stock offering
devices
Smith & Nephew names new chairman, posts Q3 profit slip
Smith & Nephew names new chairman, posts Q3 profit slip
Mass Device
Smith & Nephew
earnings
devices
Reckitt Heroin-Abuse Drug Seen Luring Shire: Real M&A
Reckitt Heroin-Abuse Drug Seen Luring Shire: Real M&A
Bloomberg
Reckitt Benckiser
heroin abuse
Shire
M&A
Suboxone
Actavis
New two-hormone Roche drug shows promise in diabetes, obesity
New two-hormone Roche drug shows promise in diabetes, obesity
Reuters
Roche
obesity
diabetes
GLP-1 agonist
Drug-maker Valeant eyes small and large M&A deals
Drug-maker Valeant eyes small and large M&A deals
Reuters
M&A
Valeant Pharmaceuticals
CytRx's aldoxorubicin shows further positive interim data in Phase 2b trial
CytRx's aldoxorubicin shows further positive interim data in Phase 2b trial
The Fly on the Wall
CytRx
aldoxorubicin
soft tissue sarcomas
EntreMed commences ENMD-2076 Phase 2 trial
EntreMed commences ENMD-2076 Phase 2 trial
The Fly on the Wall
ENMD-2076
EntreMed
ovarian cancer
DOJ wants info from AstraZeneca about heart drug study
DOJ wants info from AstraZeneca about heart drug study
Bizjournals.com
DOJ
AstraZeneca
Brilinta
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »